Category: Blog

Featured

NIA Reports Senolytics Show Potential to Protect Against Coronavirus in Older Mice

The NIA reports: “Cellular senescence, an aging mechanism in which cells lose normal function, may contribute to a worse response in human cells to COVID-19 and in older mice to a similar coronavirus — but a class of drug known as senolytics decreased adverse responses and increased survival for the mice. The preclinical findings from a study funded in part by NIA were recently published in Science.”

This is also the focus of one of SRF’s projects that is working on selectively removing senescent cells and reversing the damage caused by them to rejuvenate the immune system.

Read More »
Featured

SENS Research Foundation wishes you Happy International Longevity Day and Longevity Month!

The United Nations General Assembly voted to establish October 1st as the ‘International Day of Older Persons’ as recorded in Resolution 45/106. The holiday was observed for the first time on October 1st, 1991.

Following this tradition, longevity research activists from around the world call this day and the month of October; International Longevity Day and International Longevity Month.

Read More »
Featured

Annual Mitochondrial Disease Awareness Week 2021

SENS Research Foundation joins the Mitochondrial Medicine Society and MITOAction.org during the third week of September in raising awareness for the Annual Mitochondrial Disease Awareness Week.

Mitochondrial function declines with age, and these dysfunctional mitochondria adversely contribute to several metabolic and neuromuscular diseases. The mitoSENS team is working tirelessly to help discover the science to reverse and/or prevent damage to mitochondrial DNA. 

Read More »
Blog

Hyperbolic Hyperbaric “Age Reversal”

Lower-quality, clickbait-hungry media outlets love sensationalist claims, but one does expect better from the public relations department of an internationally-respected research university. And it was an easy jump from the already-overstated “In First, Aging Stopped in Humans” and “treatments can reverse two processes associated with aging and its illnesses” to saying that a treatment “can reverse

Read More »
Featured

Altos Labs recruits star researchers for rejuvenation therapeutics

As reported in the MIT Technology Review, the rejuvenation start-up is recruiting top researchers to work on “unfettered blue-sky research on how cells age and how to reverse that process.” Milner, a billionaire investor and science enthusiast, and Amazon founder Jeff Bezos are said to be investing in the venture that has so far brought on Juan Carlos Izpisúa Belmonte from the Salk Institute, UCLA professor Steve Horvath, and Nobel Prize winning scientist Shinya Yamanaka, who will chair the scientific advisory board.

Read More »

Senotherapeutics Report

With sponsorship from SRF, Longevity.Technology’s Market Intelligence Unit has published a report examining the potential of targeting cell senescence to treat many major diseases – particularly including current and upcoming investment opportunities – accompanied by a foreword written by SRF Chief Science Officer, Dr. Aubrey de Grey.

Read More »

Double Your Impact

If you’ve invested in a donor-advised fund (DAF), you know that a key advantage of these funds is that they let you put charitable money aside when you have a jump in earnings, and watch for the best time and project to invest your money. We’re here (along with special guest Herbie Hancock) to tell you that now is that time!

Read More »

COVID-19 and Aging

Why is the novel coronavirus so deadly to the elderly? We outline some of the ways in which aging is relevant to diseases like COVID-19 – and how our research may help render future viruses far less dangerous.

Read More »

Smart Bombs Against Senescent Cells

Summary: A new nanotechnology enables the selective targeting of senescent cells; in mice, it dramatically improves an age-related lung disease, and makes cancer chemotherapy safer and more effective. Now the scientists behind it have a startup and are headed toward human testing.

Read More »

Pathway To New Therapies

Article by Michael Rae about recent and forthcoming regulatory reforms required to support the testing of new therapies for Alzheimer’s and other age-related diseases.

Read More »

Human Trials of Two New Rejuvenation Biotechnologies Targeting Alpha-Synuclein

Alpha-synuclein aggregates are a key form of aging damage in the brain, linked to a spectrum of symptoms in Parkinson’s disease beyond the classic motor symptoms. The first amyloSENS-style immunotherapy to clear this pathology out of the brain was advanced into clinical trials by Austrian biotech firm AFFiRiS AG. Now two more such therapies have entered human testing. Although the trials are in their earliest stages, they bring the hope that this rejuvenation biotechnology will begin preventing and reversing Parkinson’s disease and less specific disorders of aging soon.

Read More »

Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.

© 2024 SENS Research Foundation – ALL RIGHTS RESERVED

Thank you for Subscribing to the SENS Research Foundation Newsletter.

You can also

or

You can